Long-term safety and efficacy of adalimumab in psoriasis: a multicentric study focused on infections (connecting study)

Alessandra Narcisi; Nicoletta Bernardini; Diego Orsini; Magda D’Agostino; Catia Felice; Alessandro Di Stefani; Valentina Carboni; Antonio Costanzo; Claudio Mastroianni

doi:10.5114/ada.2020.96910

eISSN: 2299-0046
ISSN: 1642-395X

Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii

Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

3/2020
vol. 37

Send email

Copy url:

abstract:

Original paper

Long-term safety and efficacy of adalimumab in psoriasis: a multicentric study focused on infections (connecting study)

Alessandra Narcisi

^{1, 2}

,

Nicoletta Bernardini

³

,

Diego Orsini

⁴

,

Magda D’Agostino

⁵

,

Catia De Felice

⁶

,

Alessandro Di Stefani

⁵

,

Valentina Carboni

⁷

,

Antonio Costanzo

^{1, 2}

,

Claudio Mastroianni

⁸

Humanitas Clinical and Research Center, Skin Pathology Lab, Rozzano-Milan, Italy
Dermatology Unit, Department of Biomedical Sciences, Humanitas University, Rozzano-Milan, Italy
Dermatology Unit “Daniele Innocenzi”, University of Rome “Sapienza”, I Faculty of Medicine and Surgery, Polo Pontino,Terracina (LT), Italy
IFO San Gallicano Institute (IRCCS), Infectious Dermatology and Allergology Unit, Rome, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
IFO San Gallicano Institute (IRCCS), Psoriasis Unit, Rome, Italy
Dermatology Unit ASL Rm-H, Frascati (RM), Italy
Infectious Disease Unit, Department of Public Health and Infectious Diseases, University of Rome “Sapienza”, Policlinico Umberto I Hospital of Rome, Italy

Adv Dermatol Allergol 2020; XXXVII (3): 428-434

DOI: https://doi.org/10.5114/ada.2020.96910

Online publish date: 2020/07/16

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Narcisi A, Bernardini N, Orsini D, et al. Long-term safety and efficacy of adalimumab in psoriasis: a multicentric study focused on infections (connecting study). Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2020;37(3):428-434. doi:10.5114/ada.2020.96910.

APA

Narcisi, A., Bernardini, N., Orsini, D., D’Agostino, M., Felice, C. D.,  & Di Stefani, A. et al. (2020). Long-term safety and efficacy of adalimumab in psoriasis: a multicentric study focused on infections (connecting study). Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 37(3), 428-434. https://doi.org/10.5114/ada.2020.96910

Chicago

Narcisi, Alessandra, Nicoletta Bernardini, Diego Orsini, Magda D’Agostino, Catia D Felice, Alessandro Di Stefani,  and Valentina Carboni et al. 2020. "Long-term safety and efficacy of adalimumab in psoriasis: a multicentric study focused on infections (connecting study)". Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii 37 (3): 428-434. doi:10.5114/ada.2020.96910.

Harvard

Narcisi, A., Bernardini, N., Orsini, D., D’Agostino, M., Felice, C., Di Stefani, A., Carboni, V., Costanzo, A.,  and Mastroianni, C. (2020). Long-term safety and efficacy of adalimumab in psoriasis: a multicentric study focused on infections (connecting study). Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 37(3), pp.428-434. https://doi.org/10.5114/ada.2020.96910

MLA

Narcisi, Alessandra et al. "Long-term safety and efficacy of adalimumab in psoriasis: a multicentric study focused on infections (connecting study)." Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, vol. 37, no. 3, 2020, pp. 428-434. doi:10.5114/ada.2020.96910.

Vancouver

Narcisi A, Bernardini N, Orsini D, D’Agostino M, Felice C, Di Stefani A et al. Long-term safety and efficacy of adalimumab in psoriasis: a multicentric study focused on infections (connecting study). Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2020;37(3):428-434. doi:10.5114/ada.2020.96910.

Introduction
This Italian multicenter retrospective study evaluated safety and efficacy of the anti-TNF drug, adalimumab, in a cohort of patients affected by tuberculosis (TB), hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV). Psoriasis is an autoimmune disease affecting around 3% of the Italian population and associated with several comorbidities, including arthritis, cardio-metabolic diseases and depression. In its moderate-to-severe form, psoriasis profoundly impairs quality of life of patients.

Aim
Therefore, these patients deserve systemic treatments including conventional DMARDS (disease modifying anti-rheumatic drugs) and biologics. Management of moderate and severe psoriasis patients affected by relevant infections such as TB, HBV, HCV and HIV may be difficult because of the toxicity of the conventional systemic treatment.

Material and methods
The CONNECTING study analysed 28 moderate to severe psoriasis patients infected by TB, HBV, HCV and HIV who were treated with adalimumab for up to 96 weeks together with respective prophylactic treatment.

Results
We observed a rapid decrease in PASI (psoriasis area severity index) reaching a 75% improvement in 91% of patients. Some of these patients (n = 9) were also affected by arthritic comorbidity. The patients experienced a rapid decrease in pain, measured by pain VAS (visual analogic scale) that reached 0 in all of them. Monitoring of the respective infection did not show any worsening or reactivation of infection or any severe adverse events during the entire observation period.

Conclusions
Adalimumab is effective and safe in patients affected by these important infections.

keywords:

Long-term safety and efficacy of adalimumab in psoriasis: a multicentric study focused on infections (connecting study)

Alessandra Narcisi 1, 2 , Nicoletta Bernardini 3 , Diego Orsini 4 , Magda D’Agostino 5 , Catia De Felice 6 , Alessandro Di Stefani 5 , Valentina Carboni 7 , Antonio Costanzo 1, 2 , Claudio Mastroianni 8

psoriasis, infection, biological drugs, adalimumab, efficacy, safety

Alessandra Narcisi

^{1, 2}

,

Nicoletta Bernardini

³

,

Diego Orsini

⁴

,

Magda D’Agostino

⁵

,

Catia De Felice

⁶

,

Alessandro Di Stefani

⁵

,

Valentina Carboni

⁷

,

Antonio Costanzo

^{1, 2}

,

Claudio Mastroianni

⁸